menu
    • menu

    Company profile for Gilgamesh Pharmaceuticals

    NEW Drugs in Dev: 4
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Gilgamesh is a clinical stage biotech developing novel medicines that harness the therapeutic promise of psychedelics to revolutionize the treatment of mental illness Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic...
    Gilgamesh is a clinical stage biotech developing novel medicines that harness the therapeutic promise of psychedelics to revolutionize the treatment of mental illness Gilgamesh is a pioneering early-stage biotech developing novel compounds that build upon the benefits of classic psychedelics with improvements of other components such as safety, tolerability, duration, and efficacy. Mental health worldwide has reached epidemic proportions and novel treatments have not kept pace with the urgent need to treat depression, anxiety, drug addiction and many other devastating diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Gilgamesh PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    113 University Place, Suite 1019, NY, NY 10003
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.gilgameshpharmaceutical.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/gilgamesh-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/gilgameshrx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Abbvie CSO Highlights Breakthrough Psychedelic Therapy; J&J's
    Abbvie CSO Highlights Breakthrough Psychedelic Therapy; J&J's

    06 Feb 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/abbvie-cso-touts-breakthrough-type-therapy-psychedelic-as-j-js-spravato-keeps-growing

    BIOSPACE
    06 Feb 2026
    Share Share
    Gilgamesh Pharma Reports Positive Phase 2A Results
    Gilgamesh Pharma Reports Positive Phase 2A Results

    06 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/gilgamesh-pharma-announces-positive-topline-phase-2a-results-for-blixeprodil-gm-1020-in-major-depressive-disorder-302653958.html

    PR NEWSWIRE
    06 Jan 2026
    Share Share
    AbbVie Completes Acquisition of Gilgamesh Pharma' Bretisilocin
    AbbVie Completes Acquisition of Gilgamesh Pharma' Bretisilocin

    17 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-gilgamesh-pharmaceuticals-bretisilocin-302587587.html

    PR NEWSWIRE
    17 Oct 2025
    Share Share
    Enveric Bio Hires IP Firm to Defend Patent Linked to AbbVie Deal
    Enveric Bio Hires IP Firm to Defend Patent Linked to AbbVie Deal

    15 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-15/enveric-biosciences-hires-ip-powerhouse-to-defend-its-us-patent-with-claims-relevant-to-bretisiloc

    PHARMIWEB
    15 Oct 2025
    Share Share
    AbbVie Buys Gilgamesh’s Depression Drug for $1.2B
    AbbVie Buys Gilgamesh’s Depression Drug for $1.2B

    26 Aug 2025

    // PRESS RELEASE

    https://news.abbvie.com/2025-08-25-AbbVie-to-Acquire-Gilgamesh-Pharmaceuticals-Bretisilocin,-a-Novel,-Investigational-Therapy-for-Major-Depressive-Disorder,-Expanding-Psychiatry-Pipeline

    PRESS RELEASE
    26 Aug 2025
    Share Share
    AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal
    AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal

    31 Jul 2025

    // REUTERS

    https://www.reuters.com/legal/transactional/abbvie-talks-acquire-gilgamesh-pharmaceuticals-bloomberg-news-reports-2025-07-30/

    REUTERS
    31 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search